Valuation: Edesa Biotech, Inc.

Market Cap 34.72M 30.87M 28.61M 26.03M 49.12M 3.3B 49.91M 344M 135M 1.72B 130M 128M 5.48B P/E 2026 *
-1.29x
P/E 2027 * -1.24x
Enterprise Value 34.72M 30.87M 28.61M 26.03M 49.12M 3.3B 49.91M 344M 135M 1.72B 130M 128M 5.48B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.45%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-26.78%
Current month-38.95%
1 month-37.92%
3 months-61.06%
6 months-56.66%
Current year+80.99%
1 week 2.52
Extreme 2.52
3.09
1 month 2.52
Extreme 2.52
4.27
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
62.65
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Free

Founder

6,893 0.0510%
1/9/26 Free

Founder

5,714 0.0593%
3/8/26 Free

Founder

5,324 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-26.78%+9.02%-37.32% 34.72M
-6.60%-8.56%+49.38%+64.90% 65B
+0.73%+6.13%+10.16%+78.13% 51.2B
-0.08%-0.85%-0.41%+61.27% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-0.72%+0.04%+25.25%+25.28% 22.5B
Average -1.79%-2.72%+42.55%+89.88% 37.24B
Weighted average by Cap. -1.91%-0.26%+44.60%+105.40%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.58M -14.44M -13.14M -24.79M -1.66B -25.19M -174M -68.05M -868M -65.77M -64.37M -2.77B -23.88M -21.23M -19.67M -17.9M -33.78M -2.27B -34.32M -236M -92.72M -1.18B -89.61M -87.71M -3.77B
Net Debt - -
Projected Income Statement - Annual - Edesa Biotech, Inc.
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
16/10/26 USD 2.570 -3.75% 64,031
15/10/26 USD 2.670 +0.75% 75,822
14/10/26 USD 2.650 -6.85% 72,593
13/10/26 USD 2.845 -3.23% 61,373
12/10/26 USD 2.940 -16.24% 81,658
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Edesa Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.570USD
Average target price
16.33USD
Spread / Average Target
+535.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Edesa Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. EDSA Stock